Morgan Stanley’s Ambrx Biopharma Inc AMAM Stock Holding History

Morgan Stanley’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,552	Closed	-$720K	–	8055
2023 Q4	$720K	Buy	50,552 +25,981	+106%	+$295K	﹤0.01%	5458
2023 Q3	$283K	Buy	24,571 +21,501	+700%	+$293K	﹤0.01%	5429
2023 Q2	$50.5K	Buy	3,070 +3,028	+7,210%	+$38.1K	﹤0.01%	6209
2023 Q1	$375	Buy	+42	New	+$211	﹤0.01%	7461
2022 Q2	–	Sell	-2,800	Closed	-$12K	–	8078
2022 Q1	$12K	Hold	2,800	–	–	﹤0.01%	7359
2021 Q4	$25K	Hold	2,800	–	–	﹤0.01%	7132
2021 Q3	$38K	Buy	+2,800	New	+$50.4K	﹤0.01%	6836

Morgan Stanley's AMAM Position: Q1 2024 in Review

Morgan Stanley sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 50,552 shares — an estimated $720K sold.

Morgan Stanley first reported a position in AMAM in Q3 2021 and held it in 7 quarters. The position peaked at $720K in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Morgan Stanley reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 50,552 Ambrx Biopharma Inc shares in Q1 2024, an estimated $720K.
Morgan Stanley first reported a position in Ambrx Biopharma Inc in Q3 2021 and held it in 7 quarters.
Morgan Stanley's Ambrx Biopharma Inc position peaked at $720K in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.